Evercyte to showcase latest cell-based advances at BIO Asia Tokyo

Vienna, Austria: – Innovative biotech manufacturer Evercyte will showcase its cell-based products and services at the 12th Annual Bio Asia International Conference in Tokyo, Japan.

Evercyte’s Chief Technology Officer and co-founder, Regina Grillari, will lead the team at the Grand Hyatt in Tokyo.

Now in its 12th year, the annual BIO Asia event brings together the world’s leading biotechnology companies and professionals engaged in the Japan-Pacific area to create a convention that offers the opportunity to network with existing clients and create new business relationships.

IPS and hTERT advances

“We’re really looking forward to using BIO Asia’s excellent networking and partnering sessions to get together with prospective customers and partners,” said Dr. Grillari.

“We have a great deal to discuss and offer, ranging from our latest technologies in assay development to the many breakthrough opportunities created by our advances in hTERT and iPS technologies,” Dr. Grillari added.

B-different breakthrough

Late last year, Evercyte announced it had made significant breakthroughs in the development of ‘B-different’ human patient-specific B-cells from urine-derived induced pluripotent stem cells (IPS).
Its joint development project with the Children’s Cancer Research Institute in Vienna has provided a platform to advance the science of generating B-cells for basic research and personalized cell based therapies.

About Evercyte

Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; including primary/normal cells; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from adult or induced pluripotent stem cells.

Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.

Systematically establishing and commercializing relevant cell model systems from donors of different genetic backgrounds, Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population.

About Bio Asia

The BIO Asia International Conference is an exclusive, customized partnering forum co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA).

The convention forms one of the Asia-Pacific region’s premier networking and knowledge-sharing platforms for US and European drug development companies to explore potential licensing and research collaborations with Asian biotech and pharmaceutical partners.

The conference also provides a chance to gain insights key opinion and policy leaders into emerging developments, challenges and opportunities for the Japanese biotech market.

The 12th Annual BIO Asia International Conference will be a two-day event, held March 24-25 at the Grand Hyatt hotel in Tokyo. It will feature keynote addresses from Dr. Tatsuya Kondo, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA); Osamu Nagayama, CEO of Chugai Pharmaceutical Co. and Shire’s CEO, Dr. Flemming Ornskov.

The event will also use BIO’s proprietary state-of-the-art IT to facilitate pre-arranged one-on-one meetings between senior-level executives.